Trials / Completed
CompletedNCT07052838
Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia
A Multicenter, Single-Arm, Open-Label Phase III Clinical Study Evaluating the Efficacy and Safety of HSK39297 Tablets in Paroxysmal Nocturnal Hemoglobinuria Patients With Anemia Despite Stable Anti-C5 Antibody Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of HSK39297 tablets in paroxysmal nocturnal hemoglobinuria (PNH) patients with anemia after stable treatment of anti-C5 antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK39297 tablets | 200mg QD |
Timeline
- Start date
- 2025-05-12
- Primary completion
- 2025-12-23
- Completion
- 2026-01-05
- First posted
- 2025-07-07
- Last updated
- 2026-02-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07052838. Inclusion in this directory is not an endorsement.